Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT839 in Autoimmune Diseases
NCT07800871Phase 2Recruiting
- Sponsor
- Fate Therapeutics
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of FT839 in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), sponsored by Fate Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
FT839
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathies (IIM)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07800871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800871.